Literature DB >> 19500133

Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome.

WenLing Xu1, LeiLei Zhou, RuJuan Qin, HuaRong Tang, HuiLing Shen.   

Abstract

The aim of this study is to investigate the correlations among Y-box binding protein-1 (YB-1) and P-glycoprotein(P-gp) and their prognostic significance in diffuse large B-cell lymphoma (DLBCL). The expression of YB-1 and P-gp was examined immunohistochemically on 68 patients with DLBCL who were treated from 2003 to 2005. Samples were paraffin-embedded newly diagnosed DLBCL tissues taken from the surgical specimens before adjuvant chemotherapy. We determined the prognostic significance of YB-1 and its relationship with P-gp in patients with DLBCL. Of the 68 tumors examined, 42 (61.8%) were positive for YB-1 expression in the nucleus. The nuclear expression of YB-1 was significantly associated with clinical stages, bone marrow involvement, extra nodal involvement, and poor response to chemotherapy. No associations were observed between P-gp and clinical features, in context of the poor response to chemotherapy. Nuclear expression of YB-1 was correlated significantly with increased expression of P-gp patients with a nuclear YB-1 tumor had a poorer prognosis than did those with a cytoplasmic YB-1 tumor in all of the DLBCL patients (P = 0.035). Thus, correlation of YB-1 and P-gp emerged as a possible biomarker for unfavorable prognosis in DLBCL. It may provide useful information for clinicians to determine the appropriate therapy for each type of DLBCL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500133     DOI: 10.1111/j.1600-0609.2009.01285.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  YB-1 binds to GluR2 mRNA and CaM1 mRNA in the brain and regulates their translational levels in an activity-dependent manner.

Authors:  Toru Tanaka; Sachiyo Ohashi; Tomoko Funakoshi; Shunsuke Kobayashi
Journal:  Cell Mol Neurobiol       Date:  2010-07-08       Impact factor: 5.046

Review 2.  Twist as a new prognostic marker in hematological malignancies.

Authors:  F Norozi; A Ahmadzadeh; M Shahjahani; S Shahrabi; N Saki
Journal:  Clin Transl Oncol       Date:  2015-07-24       Impact factor: 3.405

3.  Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients.

Authors:  A Kolk; N Jubitz; K Mengele; K Mantwill; O Bissinger; M Schmitt; M Kremer; P S Holm
Journal:  Br J Cancer       Date:  2011-11-17       Impact factor: 7.640

Review 4.  The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.

Authors:  N Merindol; A Riquet; V Szablewski; J-F Eliaou; A Puisieux; N Bonnefoy
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037

5.  The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors.

Authors:  Elizaveta E Alemasova; Konstantin N Naumenko; Tatyana A Kurgina; Rashid O Anarbaev; Olga I Lavrik
Journal:  Oncotarget       Date:  2018-05-04

Review 6.  A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.

Authors:  Akram Alkrekshi; Wei Wang; Priyanka Shailendra Rana; Vesna Markovic; Khalid Sossey-Alaoui
Journal:  Cell Signal       Date:  2021-07-03       Impact factor: 4.850

7.  The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress.

Authors:  Ekaterina R Kim; Anastasia A Selyutina; Ilya A Buldakov; Valentina Evdokimova; Lev P Ovchinnikov; Alexey V Sorokin
Journal:  Cell Cycle       Date:  2013-10-07       Impact factor: 4.534

8.  Inhibition of YBX1 by miR-216a Suppresses Proliferation and Invasion of Diffuse Large B-Cell Lymphoma.

Authors:  Yan Li; Juan Qian; Li Yang
Journal:  Balkan Med J       Date:  2021-05       Impact factor: 2.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.